Boston Scientific Corporation $BSX Shares Sold by ZWJ Investment Counsel Inc.

Key Points

• ZWJ Investment Counsel Inc. reduced its stake in Boston Scientific Corporation by 6.3%, now holding 565,752 shares, valued at approximately $60.77 million, making it the 12th largest position in their portfolio.
• Boston Scientific recently reported quarterly earnings of $0.75 EPS, exceeding analysts' expectations, with a revenue of $5.06 billion, reflecting a year-over-year growth of 22.8%.
• Analyst ratings for Boston Scientific are generally positive, with a consensus rating of "Buy" and an average price target of $120.79, although one firm downgraded it from "buy" to "hold".

ZWJ Investment Counsel Inc. lessened its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 6.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 565,752 shares of the medical equipment provider's stock after selling 37,879 shares during the period. Boston Scientific accounts for approximately 2.3% of ZWJ Investment Counsel Inc.'s investment portfolio, making the stock its 12th biggest position. ZWJ Investment Counsel Inc.'s holdings in Boston Scientific were worth $60,767,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of BSX. Brighton Jones LLC raised its position in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after purchasing an additional 226 shares during the last quarter. Fermata Advisors LLC acquired a new position in shares of Boston Scientific during the 1st quarter worth about $287,000. Breakwater Capital Group raised its holdings in Boston Scientific by 2.9% in the 1st quarter. Breakwater Capital Group now owns 7,887 shares of the medical equipment provider's stock valued at $796,000 after acquiring an additional 221 shares during the last quarter. Foster Group Inc. acquired a new stake in Boston Scientific in the 1st quarter valued at about $287,000. Finally, Generali Investments Management Co LLC raised its holdings in Boston Scientific by 14.4% in the 1st quarter. Generali Investments Management Co LLC now owns 30,912 shares of the medical equipment provider's stock valued at $3,118,000 after acquiring an additional 3,886 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Up 1.1%

Shares of NYSE BSX opened at $97.30 on Friday. The company has a 50 day simple moving average of $102.93 and a 200-day simple moving average of $102.05. The company has a market capitalization of $144.17 billion, a P/E ratio of 57.91, a P/E/G ratio of 2.32 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's revenue was up 22.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on BSX shares. Wall Street Zen downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a report on Friday. Needham & Company LLC reiterated a "buy" rating and issued a $121.00 price objective on shares of Boston Scientific in a report on Wednesday. Canaccord Genuity Group increased their price objective on shares of Boston Scientific from $131.00 to $132.00 and gave the company a "buy" rating in a report on Wednesday. Truist Financial increased their price objective on shares of Boston Scientific from $125.00 to $129.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Barclays increased their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the company an "overweight" rating in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific has a consensus rating of "Buy" and an average price target of $120.79.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director directly owned 2,081 shares of the company's stock, valued at $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 174,214 shares of company stock worth $17,972,457. Company insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.